FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:1953-1958 June 29, 2000 Number 26 Next

	Full Text PDF Editorial by Zielinski, C. C. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background The length of time after an episode of venous thromboembolism during which the risk of newly diagnosed cancer is increased is not known, and whether vitamin K antagonists have an antineoplastic effect is controversial.

Methods In a prospective, randomized study of the duration of oral anticoagulation (six weeks or six months) after a first episode of venous thromboembolism, patients were questioned annually about any newly diagnosed cancer. After a mean follow-up of 8.1 years, we used the Swedish Cancer Registry to identify all diagnoses of cancer and causes of death in the study population. The observed numbers of cases of cancer were compared with expected numbers based on national incidence rates, and the standardized incidence ratios were calculated.

Results A first cancer was diagnosed in 111 of 854 patients (13.0 percent) during follow-up. The standardized incidence ratio for newly diagnosed cancer was 3.4 (95 percent confidence interval, 2.2 to 4.6) during the first year after the thromboembolic event and remained between 1.3 and 2.2 for the following five years. Cancer was diagnosed in 66 of 419 patients (15.8 percent) who were treated for six weeks with oral anticoagulants, as compared with 45 of 435 patients (10.3 percent) who were treated for six months (odds ratio, 1.6; 95 percent confidence interval, 1.1 to 2.4). The difference was mainly due to the occurrence of new urogenital cancers, of which there were 28 cases in the six-week group (6.7 percent) and 12 cases in the six-month group (2.8 percent) (odds ratio, 2.5; 95 percent confidence interval, 1.3 to 5.0). The difference in the incidence of cancer between the treatment groups became evident only after two years of follow-up, and it remained significant after adjustment for sex, age, and whether the thromboembolism was idiopathic or nonidiopathic. Older age at the time of the venous thrombosis and an idiopathic thromboembolism were also independent risk factors for a diagnosis of cancer. No difference in the incidence of cancer-related deaths was detected.

Conclusions The risk of newly diagnosed cancer after a first episode of venous thromboembolism is elevated during at least the following two years. Subsequently, the risk seems to be lower among patients treated with oral anticoagulants for six months than among those treated for six weeks.

Source Information

From the Department of Hematology, Karolinska Hospital, Stockholm, Sweden.

Address reprint requests to Dr. Schulman at the Coagulation Unit, Karolinska Hospital, SE-171 76 Stockholm, Sweden, or at sam.schulman{at}ks.se.

Full Text of this Article

Related Letters:

Venous Thromboembolism and Cancer
Eikelboom J. W., Mehta S. R., Hughes-Davies T.H., Roychowdhury D., Zacharski L. R., Ornstein D. L., Schulman S., Lindmarker P.
Extract | Full Text  
N Engl J Med 2000; 343:1337-1338, Nov 2, 2000. Correspondence

This article has been cited by other articles:

• Khorana, A. A., Streiff, M. B., Farge, D., Mandala, M., Debourdeau, P., Cajfinger, F., Marty, M., Falanga, A., Lyman, G. H. (2009). Venous Thromboembolism Prophylaxis and Treatment in Cancer: A Consensus Statement of Major Guidelines Panels and Call to Action. JCO 27: 4919-4926 [Abstract] [Full Text]  
• BABU, B., CARMAN, T. L. (2009). Cancer and clots: All cases of venous thromboembolism are not treated the same. Cleveland Clinic Journal of Medicine 76: 129-135 [Abstract] [Full Text]  
• Authors/Task Force Members, , Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galie, N., Pruszczyk, P., Bengel, F., Brady, A. J.B., Ferreira, D., Janssens, U., Klepetko, W., Mayer, E., Remy-Jardin, M., Bassand, J.-P., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C., Hellemans, I., Kristensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J. L., Document Reviewers, , Zamorano, J.-L., Andreotti, F., Ascherman, M., Athanassopoulos, G., De Sutter, J., Fitzmaurice, D., Forster, T., Heras, M., Jondeau, G., Kjeldsen, K., Knuuti, J., Lang, I., Lenzen, M., Lopez-Sendon, J., Nihoyannopoulos, P., Perez Isla, L., Schwehr, U., Torraca, L., Vachiery, J.-L. (2008). Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 29: 2276-2315 [Full Text]  
• Versteeg, H. H., Schaffner, F., Kerver, M., Ellies, L. G., Andrade-Gordon, P., Mueller, B. M., Ruf, W. (2008). Protease-Activated Receptor (PAR) 2, but not PAR1, Signaling Promotes the Development of Mammary Adenocarcinoma in Polyoma Middle T Mice. Cancer Res. 68: 7219-7227 [Abstract] [Full Text]  
• Versteeg, H. H., Schaffner, F., Kerver, M., Petersen, H. H., Ahamed, J., Felding-Habermann, B., Takada, Y., Mueller, B. M., Ruf, W. (2008). Inhibition of tissue factor signaling suppresses tumor growth. Blood 111: 190-199 [Abstract] [Full Text]  
• Nishioka, J., Goodin, S. (2007). Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival. J Oncol Pharm Pract 13: 85-97 [Abstract]  
• Fagnani, D, Franchi, R, Porta, C, Pugliese, P, Borgonovo, K, Bertolini, A, Duro, M, Ardizzoia, A, Filipazzi, V, Isa, L, Vergani, C, Milani, M, Cimminiello, C, On behalf of POLONORD Group, (2007). Thrombosis-related complications and mortality in cancer patients with central venous devices: an observational study on the effect of antithrombotic prophylaxis. Ann Oncol 18: 551-555 [Abstract] [Full Text]  
• Piazza, G., Goldhaber, S. Z. (2006). Acute Pulmonary Embolism: Part I: Epidemiology and Diagnosis. Circulation 114: e28-e32 [Full Text]  
• Lee, A. Y. Y. (2006). Thrombosis and Cancer: The Role of Screening for Occult Cancer and Recognizing the Underlying Biological Mechanisms. ASH Education Book 2006: 438-443 [Abstract] [Full Text]  
• Prandoni, P. (2005). How I treat venous thromboembolism in patients with cancer. Blood 106: 4027-4033 [Abstract] [Full Text]  
• White, R. H., Chew, H. K., Zhou, H., Parikh-Patel, A., Harris, D., Harvey, D., Wun, T. (2005). Incidence of Venous Thromboembolism in the Year Before the Diagnosis of Cancer in 528 693 Adults. Arch Intern Med 165: 1782-1787 [Abstract] [Full Text]  
• Goldhaber, S. Z. (2005). Tamoxifen: Preventing Breast Cancer and Placing the Risk of Deep Vein Thrombosis in Perspective. Circulation 111: 539-541 [Full Text]  
• Zacharski, L. R., Prandoni, P., Monreal, M. (2005). Warfarin Versus Low-Molecular-Weight Heparin Therapy in Cancer Patients. The Oncologist 10: 72-79 [Abstract] [Full Text]  
• Kakkar, A. K., Levine, M. N., Kadziola, Z., Lemoine, N. R., Low, V., Patel, H. K., Rustin, G., Thomas, M., Quigley, M., Williamson, R. C.N. (2004). Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS). JCO 22: 1944-1948 [Abstract] [Full Text]  
• Goldhaber, S. Z., Elliott, C. G. (2003). Acute Pulmonary Embolism: Part I: Epidemiology, Pathophysiology, and Diagnosis. Circulation 108: 2726-2729 [Full Text]  
• Lee, A. Y.Y., Levine, M. N. (2003). Venous Thromboembolism and Cancer: Risks and Outcomes. Circulation 107: I-17-21 [Abstract] [Full Text]  
• Hembrough, T. A., Swartz, G. M., Papathanassiu, A., Vlasuk, G. P., Rote, W. E., Green, S. J., Pribluda, V. S. (2003). Tissue Factor/Factor VIIa Inhibitors Block Angiogenesis and Tumor Growth Through a Nonhemostatic Mechanism. Cancer Res. 63: 2997-3000 [Abstract] [Full Text]  
• Nagai, K., Arai, H., Yanagita, M., Matsubara, T., Kanamori, H., Nakano, T., Iehara, N., Fukatsu, A., Kita, T., Doi, T. (2003). Growth Arrest-specific Gene 6 Is Involved in Glomerular Hypertrophy in the Early Stage of Diabetic Nephropathy. J. Biol. Chem. 278: 18229-18234 [Abstract] [Full Text]  
• Madari, H., Panda, D., Wilson, L., Jacobs, R. S. (2003). Dicoumarol: A Unique Microtubule Stabilizing Natural Product that Is Synergistic with Taxol. Cancer Res. 63: 1214-1220 [Abstract] [Full Text]  
• Samuels, M. A., King, M. E., Balis, U. (2002). Case 31-2002 - A 61-Year-Old Man with Headache and Multiple Infarcts. NEJM 347: 1187-1194 [Full Text]  
• Meyer, G., Marjanovic, Z., Valcke, J., Lorcerie, B., Gruel, Y., Solal-Celigny, P., Le Maignan, C., Extra, J. M., Cottu, P., Farge, D. (2002). Comparison of Low-Molecular-Weight Heparin and Warfarin for the Secondary Prevention of Venous Thromboembolism in Patients With Cancer: A Randomized Controlled Study. Arch Intern Med 162: 1729-1735 [Abstract] [Full Text]  
• Yanagita, M., Arai, H., Ishii, K., Nakano, T., Ohashi, K., Mizuno, K., Varnum, B., Fukatsu, A., Doi, T., Kita, T. (2001). Gas6 Regulates Mesangial Cell Proliferation through Axl in Experimental Glomerulonephritis. Am. J. Pathol. 158: 1423-1432 [Abstract] [Full Text]  
• Sorensen, H. T., Mellemkjar, L., Olsen, J. H., Baron, J. A. (2000). Prognosis of Cancers Associated with Venous Thromboembolism. NEJM 343: 1846-1850 [Abstract] [Full Text]  
• Eikelboom, J. W., Mehta, S. R., Hughes-Davies, T.H., Roychowdhury, D., Zacharski, L. R., Ornstein, D. L., Schulman, S., Lindmarker, P. (2000). Venous Thromboembolism and Cancer. NEJM 343: 1337-1338 [Full Text]  
• Zielinski, C. C., Hejna, M. (2000). Warfarin for Cancer Prevention. NEJM 342: 1991-1993 [Full Text]  
• Brar, S. S., Kennedy, T. P., Sturrock, A. B., Huecksteadt, T. P., Quinn, M. T., Whorton, A. R., Hoidal, J. R. (2002). An NAD(P)H oxidase regulates growth and transcription in melanoma cells. Am. J. Physiol. Cell Physiol. 282: C1212-C1224 [Abstract] [Full Text]